OraSure Technologies withdrew its FDA 510(k) and CLIA waiver submission for its InteliQuick CT/NG point-of-care molecular test after discussions with the agency. The company disclosed the move will push clearance beyond its targeted 2026 launch and alter milestone economics tied to its acquisition of Sherlock Biosciences. OraSure said it expects incremental costs from a resubmission but believes these should be offset by reductions in milestone payments related to the regulatory delay. In an SEC filing, the company stated it withdrew the submission in July, meaning it is no longer obligated to pay the milestone contingent payments outlined in the merger terms, with liability reduced to zero. The test is designed for rapid detection of Chlamydia trachomatis and Neisseria gonorrhoeae using isothermal nucleic acid amplification in about 30 minutes, intended for point-of-care and at-home use. The original submission was filed in January. The development is a cautionary case for digital and molecular diagnostics companies managing regulatory timelines after acquisitions, where milestone structures can materially impact reported R&D and contingent consideration values.